Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis
K Deshpande, V Martirosian, BN Nakamura… - Neuro …, 2022 - academic.oup.com
Background Brain metastases (BM) are responsible for neurological decline and poor
overall survival. Although the pro-metastatic roles of glial cells, and the acquisition of …
overall survival. Although the pro-metastatic roles of glial cells, and the acquisition of …
Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond
A Rodriguez, MS Ahluwalia, C Bettegowda… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Implementation of standardized protocols in neurooncology during the surgical resection of
brain tumors is needed to advance the clinical treatment paradigms that use tissue for …
brain tumors is needed to advance the clinical treatment paradigms that use tissue for …
Comparison of Resection Assisting Devices in the Process of Collecting Brain Tumor Tissue for Basic Research: Microdebrider Versus Ultrasonic Aspirator
YM Zohdy, M Saini, J Heit, S Neill, B Morales-Vargas… - World Neurosurgery, 2024 - Elsevier
Introduction Brain tumors display significant inter and intratumoral heterogeneity, impacting
disease progression and outcomes. Preserving surgically resected tissue is vital for …
disease progression and outcomes. Preserving surgically resected tissue is vital for …
Epigenetic dysregulation in meningiomas
MA Wedemeyer, I Muskens, BA Strickland… - Neuro-oncology …, 2022 - academic.oup.com
Background Meningiomas are the most common primary brain tumor. Though typically
benign with a low mutational burden, tumors with benign histology may behave aggressively …
benign with a low mutational burden, tumors with benign histology may behave aggressively …
[PDF][PDF] Neuro-Oncology Advances
MA Wedemeyer, I Muskens, BA Strickland, O Aurelio… - 2022 - pdfs.semanticscholar.org
Background. Meningiomas are the most common primary brain tumor. Though typically
benign with a low mutational burden, tumors with benign histology may behave aggressively …
benign with a low mutational burden, tumors with benign histology may behave aggressively …
[PDF][PDF] A. Personal Information: Name Thomas C. Chen, MD, Ph. D., MHA, FACS Business Address
B Education - joshshachar.com
8. Potent enhancement of conventional multiple myeloma chemotherapy by DMC, a novel
drug with multifunctional molecular applications. Multiple Myeloma Foundation. Co-PI, 2005 …
drug with multifunctional molecular applications. Multiple Myeloma Foundation. Co-PI, 2005 …